Using PET/MRI to improve detection of lymph node metastases in cervical cancer
Contribution of PET/MRI in Locally Advanced Cervical Cancer
Centre Paul Strauss · NCT06083103
This study is testing if a new imaging method called PET/MRI can better find lymph node cancer spread in patients with advanced cervical cancer compared to the standard PET/CT scan.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centre Paul Strauss (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06083103 on ClinicalTrials.gov |
What this trial studies
This observational trial aims to evaluate the effectiveness of 18F-FDG positron emission tomography-magnetic resonance imaging (PET/MRI) compared to standard PET/CT in detecting lymph node metastases in patients with locally advanced cervical cancer. The study will involve patients aged 18 and older who are undergoing pre-treatment assessment for cervical cancer stages IB2 to IVA. Both imaging techniques will be performed sequentially using the same dose of radiotracer to ensure consistency in results.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older with presumed cervical cancer stages IB2 to IVA who are undergoing pre-treatment assessment.
Not a fit: Patients with a history of other cancers that could affect imaging results or those with contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of lymph node metastasis detection in cervical cancer, leading to better treatment planning.
How similar studies have performed: Previous studies have shown that PET/MRI may have better sensitivity than PET/CT in detecting metastatic lymph nodes, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged from 18 years old and over * Patients with presumed cervical cancer of stages IB2 to IVA based on clinical data and pelvic MRI, undergoing pre-treatment assessment. * For women of childbearing potential : Adequate contraception throughout study participation. Note : enrollment in a concomitant clinical trial is authorized Exclusion Criteria: * Oncological history that could possibly interfere with imaging results interpretation, apart from cervical cancer * Extra-nodal metastasis clinically or radiologically proven before study participation * Contraindication to MRI or injection of contrast agents containing gadolinium * Contraindication to lumbo-aortic lymphadenectomy * Persons deprived of liberty * Minor or patients placed under guardianship or supervision * Patient under judicial protection * Patient unable to consent
Where this trial is running
Strasbourg
- Institut de cancérologie Strasbourg Europe — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Claire VIT
- Email: promotion-rc@icans.eu
- Phone: (0)3 88 25 85 29
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cervical Cancer